At a Glance
Retatrutide and tirzepatide are both engineered incretin receptor agonist peptides, and they are frequently compared in research because they sit one rung apart on the receptor-engagement ladder. The single defining difference is the glucagon receptor: retatrutide engages it, tirzepatide does not.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Agonist class | Triple agonist | Dual agonist |
| Receptor targets | GIP + GLP-1 + glucagon | GIP + GLP-1 |
| Glucagon receptor activity | Yes | No |
| Development code | LY3437943 | LY3298176 |
| CAS number | 2381089-83-2 | 2023788-19-2 |
| Molecular formula | C221H342N46O68 (reported) | C225H348N48O68 |
| Molecular weight | ≈ 4731.4 g/mol | ≈ 4813.45 g/mol |
| Compound type | Synthetic peptide | Synthetic 39-residue peptide |
| Physical form | Lyophilized powder | Lyophilized powder |
| Research status | Newer triple-agonist reference | Established dual-agonist reference |
| Intended use | Laboratory research only | Laboratory research only |
Mechanism Comparison
Both compounds are studied as agonists at G-protein-coupled incretin receptors, and both engage the GIP and GLP-1 receptors. The distinction is the third target. Tirzepatide stops at two receptors — it is the reference dual GIP / GLP-1 agonist. Retatrutide adds activity at the glucagon receptor, making it a triple agonist.
In research terms, this is why the two are studied side by side: a controlled comparison isolates the contribution of glucagon-receptor engagement, since the GIP and GLP-1 components are shared. Researchers examine each compound's signaling profile through downstream readouts such as cyclic AMP (cAMP) accumulation, and compare potency across receptor subtypes using standard pharmacology measures.
Structural Notes
Both are large synthetic peptides of similar size — retatrutide near 4731 g/mol and tirzepatide near 4813 g/mol. Each carries backbone modifications and acylation that extend stability relative to the native incretin hormones. Their close molecular weights mean reconstitution math is broadly similar; use the Reconstitution Calculator to compute concentration and draw volumes for any vial size.
Which Is "Better"?
Neither compound is "better" — they are different research tools. A dual agonist and a triple agonist answer different research questions. Selection in a research setting depends entirely on the receptor profile a given study is designed around. For deeper background on the receptor framework, see the GLP Research Overview; for compound-specific data, see the Retatrutide Guide and Tirzepatide Guide.
Both compounds are sold strictly for laboratory and in-vitro research. They are not for human consumption, veterinary use, or any diagnostic or therapeutic application. This comparison is research reference material, not medical or dosing advice.